Device and method for extended delivery of pharmacologically active agents to the ear
AssigneeMinnesota Mining and Manufacturing Company
InventorsDavid C. Muchow, Larry M. Sirvio
Life of this patent
Estimating the term…
Abstract
A device useful for the treatment of infections of the middle ear in a prophylactic manner. A preferred device involves the use of a biodegradable support incorporating a therapeutically active agent, such as a drug. The device can be surgically inserted into the middle ear and there expand in order to substantially contact the walls of the middle ear. As it biodegrades, the expanded device provides prolonged, responsive release of active agent to the middle ear.
Claims5
A method of treating otitis media comprising inserting into the middle ear a biodegradable, substantially permeable support device incorporating a therapeutically effective releasable amount of at least one pharmacologically active agent selected from the group consisting of antibacterials, antivirals, antifungals, fluorides, salts, glycerine and antiinflammatory medications, the characteristics of the device being that (1) the device is a cylindrical sheet or coiled filament retained or retainable in an insertable shape of initial dimensions that allow it to be surgically inserted into the middle ear;
- (2) upon insertion into the middle ear, the device is capable of expanding towards its original shape in order to provide a surface that substantially contacts the walls of the middle ear without substantially occluding the middle ear space;
- and (3) once expanded, the device is capable of providing extended release of the active agent to the middle ear.
A method of delivering pharmacologically active agents to the middle ear comprising inserting into the middle ear a biodegradable, substantially permeable support device incorporating a therapeutically effective releasable amount of at least one pharmacologically active agent, the characteristics of the device being such that (1) the device is provided retained or retainable in an insertable shape of initial dimensions that allow it to be surgically inserted into the middle ear;
- (2) upon insertion into the middle ear, the device is capable of expanding towards its original shape in order to provide a surface that substantially contacts the walls of the middle ear without substantially occluding the middle ear space;
- and (3) once expanded, the device is capable of providing extended release of the active agent to the middle ear;
- wherein the insertable shape is a cylindrical sheet having initial dimensions of a diameter of less than about 2 mm, a length of about 1 cm, and wherein the sheet unrolls in the middle ear to form a tube of on the order of 1 cm circumference and about 0.4 cm to about 0.6 cm diameter;
- wherein the support is made of a material selected from the group consisting of polyesteramides, polyglycolic acid, polylactic acid, copolymers of glycolide and lactide, polyvinyl alcohol, copolymers of polyethylene oxide and polylactic acid, and chemically modified coilagent compounds;
- and
- wherein the pharmacologically active agent is selected from the group consisting of antibacterials, antivirals, antifungals, osmotic agents, fluorides and antiinflammatory medications.
A device to deliver pharmacologically active agents to the middle ear consisting essentially of biodegradable, substantially permeable support, incorporating a therapeutically effective releasable amount of at least one pharmacologically active agent selected from the group consisting of antibacterials, antivirals, antifungals, fluorides, salts, glycerine and antiinflammatory medications, the characteristics of the device being that (1) the device is retained or retainable as coiled filament having initial dimensions that allow it to be surgically inserted into the middle ear;
- (2) upon insertion into the middle ear, the device is capable of expanding towards its original shape in order to provide a surface that substantially contacts the walls of the middle ear without substantially occluding the middle ear space;
- (3) once expanded, the device is capable of providing extended release of the active agent to the middle ear;
- and (4) the support degrades within about 2-18 months when inserted into the middle ear.
Dependencies are inferred from the claim text.